{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000025","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.664727+00:00","generated_at":"2026-05-22T10:56:15.274317+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme Q1 revenue up 35% to $265M; raises FY25 guidance, announces $250M buyback","bullets":["Q1 revenue $264.9M (+35% YoY); GAAP EPS $0.93 (+55%); non-GAAP EPS $1.11 (+41%).","Raised 2025 guidance: revenue $1.2-1.28B (prev $1.15-1.225B), adj. EBITDA $790-840M, non-GAAP EPS $5.30-5.70.","Announced new $250M share repurchase; completed first $250M ASR in March 2025.","Filed patent infringement lawsuit against Merck over MDASE for subcutaneous Keytruda."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000025","json":"https://secwatch.observer/filing/0001159036-25-000025.json","markdown":"https://secwatch.observer/filing/0001159036-25-000025.md","text":"https://secwatch.observer/filing/0001159036-25-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/0001159036-25-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000025/halo-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:56:15.274317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}